FibroGen, Inc. (NASDAQ:FGEN - Get Free Report)'s share price traded down 6.7% during mid-day trading on Tuesday . The company traded as low as $6.21 and last traded at $6.21. 64,423 shares were traded during mid-day trading, a decline of 18% from the average session volume of 78,540 shares. The stock had previously closed at $6.65.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. Wall Street Zen assumed coverage on FibroGen in a research note on Saturday, May 17th. They issued a "hold" rating on the stock. William Blair restated a "market perform" rating on shares of FibroGen in a research note on Tuesday, April 1st. Finally, HC Wainwright restated a "buy" rating and issued a $250.00 price objective on shares of FibroGen in a research note on Tuesday, May 13th.
Get Our Latest Stock Analysis on FibroGen
FibroGen Trading Down 11.5%
The firm has a market cap of $594.64 million, a PE ratio of -4.80 and a beta of 0.83. The stock has a fifty day simple moving average of $0.31 and a two-hundred day simple moving average of $0.40.
FibroGen (NASDAQ:FGEN - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, missing analysts' consensus estimates of $0.75 by ($4.75). The business had revenue of $2.70 million during the quarter, compared to analyst estimates of $2.00 million. As a group, sell-side analysts predict that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.
Insider Transactions at FibroGen
In other FibroGen news, CEO Thane Wettig acquired 5,800 shares of the business's stock in a transaction dated Monday, March 24th. The stock was bought at an average price of $8.75 per share, with a total value of $50,750.00. Following the completion of the acquisition, the chief executive officer now owns 21,733 shares of the company's stock, valued at $190,163.75. This trade represents a 36.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director James A. Schoeneck acquired 10,000 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were acquired at an average cost of $8.75 per share, with a total value of $87,500.00. Following the acquisition, the director now directly owns 12,948 shares of the company's stock, valued at $113,295. This represents a 339.21% increase in their position. The disclosure for this purchase can be found here. 3.07% of the stock is owned by insiders.
Institutional Trading of FibroGen
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC purchased a new stake in FibroGen in the fourth quarter worth approximately $27,000. Velan Capital Investment Management LP bought a new stake in shares of FibroGen in the 4th quarter valued at about $42,000. XTX Topco Ltd boosted its stake in shares of FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 77,693 shares during the period. HighTower Advisors LLC boosted its stake in shares of FibroGen by 292.8% during the first quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company's stock valued at $125,000 after purchasing an additional 301,500 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of FibroGen during the fourth quarter valued at approximately $205,000. Hedge funds and other institutional investors own 72.71% of the company's stock.
About FibroGen
(
Get Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
